1 / 2

Survival and Progression-Free Time in Multiple Myeloma: Dosing Impact

Explore the impact of different dosages on survival in multiple myeloma patients. Results show median progression-free times ranging from 18.6 to 33 months. An educational session from EHA 2013 presented by Dr. S. Lonial.

selia
Download Presentation

Survival and Progression-Free Time in Multiple Myeloma: Dosing Impact

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EHA 2013 - S. Lonial, session éducationnelle myélome multiple

  2. Survie sans progression Temps médian à la progression 10 mg/kg (n = 36) : 33 mois (IC95 : 14,883-NA) 20 mg/kg (n= 37) : 18,6 mois (IC95 : 12,912-32,361) Total (n = 73) : 25,8 mois (IC95 : 15,376-35,713) EHA 2013 - S. Lonial, session éducationnelle myélome multiple

More Related